CRMD vs MRNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Jun 20, 2026

CRMD

61.2
AI Score
VS
CRMD Wins

MRNA

57.8
AI Score

Investment Advisor Scores

CRMD

61score
Recommendation
BUY

MRNA

58score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric CRMD MRNA Winner
Forward P/E 17.0068 23.0415 CRMD
PEG Ratio 0 0 Tie
Revenue Growth 226.1% 260.2% MRNA
Earnings Growth 42.8% -85.1% CRMD
Tradestie Score 61.2/100 57.8/100 CRMD
Profit Margin 45.2% -143.6% CRMD
Beta 1.00 1.00 Tie
AI Recommendation BUY HOLD CRMD

Frequently Asked Questions

Based on our detailed analysis, CRMD is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.